![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Safety, Tolerability, and Pharmacokinetics of BMS-986263/ND-L02-s0201, A Novel Targeted Lipid Nanoparticle
Delivering HSP47 siRNA, in Healthy Participants: A Randomised, Placebo-Controlled, Double-Blind, Phase 1 Study
|
|
|
Reported by Jules Levin
EASL 2018 April 11-15 Paris France
Benjamin Soule, Giridhar S. Tirucherai, Uma Kavita, Sudeep Kundu, Rose Christian
Bristol-Myers Squibb, Princeton, NJ, USA
![0425181](../images%20/042518/042518-1/0425181.gif)
![0425182](../images%20/042518/042518-1/0425182.gif)
![0425183](../images%20/042518/042518-1/0425183.gif)
![0425184](../images%20/042518/042518-1/0425184.gif)
![0425185](../images%20/042518/042518-1/0425185.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|